C - Chemistry – Metallurgy – 07 – C
Patent
C - Chemistry, Metallurgy
07
C
C07C 333/04 (2006.01) A61K 31/27 (2006.01) C07C 271/42 (2006.01) C07C 271/44 (2006.01) C07C 271/56 (2006.01) C07C 271/58 (2006.01) C07C 333/06 (2006.01) C07C 333/08 (2006.01)
Patent
CA 2275371
This invention is directed to compounds of formula (I) wherein m is from 0-4; X is 0 or S; Y is halogeno; R1 is hydrogen or C1-4 alkyl; R2 is hydrogen, C1-4 alkyl or optionally substituted propargyl; and R3 and R4 are each independently hydrogen, C1-8 alkyl, C6-12 aryl, C6-12 cycloalkyl or C6-12 aralkyl, R5 is hydrogen or C1-4 alkyl; and pharmaceutically ac-ceptable salts thereof, provided that when X is O, R2 is optionally substituted propargyl. This invention is also directed to the use of these compounds for treat-ing depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
Composés de formule (I). Dans ladite formule, m est compris entre 0 et 4; X est O ou S; Y est halogéno; R1 est hydrogène ou alkyle C1-4; R2 est hydrogène, alkyle C1-4 ou propargyle éventuellement substitué; et R3 et R4 sont chacun indépendamment hydrogène, alkyle C1-8, aryle C6-12, cycloalkyle C6-12; R5 est hydrogène ou alkyle C1-4. Egalement, sels pharmaceutiquement acceptables de ces composés, à condition que X soit O et que R2 soit propargyle éventuellement substitué. On décrit aussi l'utilisation des composés pour traiter les maladies suivantes: dépression, trouble déficitaire de l'attention, trouble de l'attention et trouble d'hyperactivité, maladie de Gilles de la Tournette, maladie d'Alzheimer et autres types de démence comme la démence sénile, la démence rattachée à la maladie de Parkinson, la démence vasculaire et la démence du corps de Lewy. On décrit enfin une composition pharmaceutique contenant une quantité thérapeutiquement efficace de ces composés et un support pharmaceutiquement acceptable.
Chorev Michael
Goren Tamar
Herzig Yacov
Sterling Jeffrey
Weinstock-Rosin Marta
Heenan Blaikie Llp
Technion Research And Development Foundation Ltd.
Teva Pharmaceutical Industries Ltd.
Yissum Research Development Company Of The Hebrew University Of
LandOfFree
Phenylethylamine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenylethylamine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylethylamine derivatives will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1744326